|
시장보고서
상품코드
1565605
세계의 백반증 치료 시장 : 유형별, 치료법별, 최종사용자별, 지역별 예측(-2030년)Global Vitiligo Treatment Market Research Report Information by Type, By Treatment, By End-User, and Region -Forecast till 2030 |
||||||
세계 백반증 치료 시장 규모는 예측 기간 동안 6.20%의 CAGR로 성장할 것으로 예상됩니다. 이 시장은 백반증 유병률 증가, 미적 매력에 대한 중요성 및 인식 증가, 치료 옵션의 발전으로 인해 성장하고 있습니다.
1인당 소득의 증가, 디지털 플랫폼의 도입, 다양한 미용 치료에 대한 인식이 높아지면서 최근 몇 년 동안 소비자들의 미적 감각이 크게 높아졌으며, ISAPS(International Society of Aesthetic International Society of Aesthetic Plastic Surgery)는 2015년부터 2019년까지 전 세계 비수술적 시술 건수가 27.3% 증가했다고 보고했습니다. 또한, ASPS(American Society of Plastic Surgeons)는 2000년부터 2017년까지 최소침습적 미용 시술의 수가 약 200% 증가했다고 보고했습니다. 또한, 2018년에는 약 1,590만 건의 최소침습적 미용 시술이 시행되었으며, 이는 2017년 대비 2% 증가한 수치입니다.
지역별 전망
2023년에는 북미 백반증 치료 시장이 가장 큰 시장 점유율을 차지했습니다. 피부 질환에 대한 인식이 높아지고, 보다 정교한 의료 인프라가 구축된 결과입니다. 이 지역이 R&D에 집중한 결과, 첨단 광선 요법, 생물학적 제제, 외용제 등 혁신적인 치료법이 도입되고 있습니다.
유럽의 시장 점유율은 백반증 치료의 통합화 추세와 유리한 의료 정책으로 인해 2위를 차지할 것으로 예상됩니다. 프랑스는 유럽 지역에서 가장 빠르게 성장하는 시장으로 예상되며, 독일이 가장 큰 점유율을 차지할 것으로 예상됩니다.
2024년부터 2032년까지 아시아태평양의 백반증 치료 시장은 가장 빠른 성장세를 보일 것으로 예측됩니다. 이는 의료비 증가와 의료 인프라 개선으로 인해 고급 치료에 대한 접근성이 높아졌기 때문입니다. 또한, 심상성 백반증의 유병률 증가와 미용 및 피부과 치료에 대한 수요 증가도 시장 성장의 원동력이 되고 있습니다.
세계 백반증 치료 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 개요
- 성장 촉진요인
- 미적 매력과 의식의 중요성 상승
- 백반증 이환율 증가
- 성장 억제요인
- 훈련을 받은 전문가의 부족
- 기회
- 임상시험 증가
제5장 시장 요인 분석
- 밸류체인 분석
- Porter's Five Forces 분석
- COVID-19가 백반증 치료 시장에 미치는 영향
제6장 세계의 백반증 치료 시장 : 유형별
- 개요
- 분절성 백반증
- 비분절성 백반증
제7장 세계의 백반증 치료 시장 : 치료 유형별
- 개요
- 치료
- 색소탈실
- 라이트
- 수술
- 피부 이식
- 블리스터 이식
- 마이크로 색소침착
- 약제
- 국소 코르티코스테로이드
- 면역억제제
제8장 세계의 백반증 치료 시장 : 최종사용자별
- 개요
- 병원
- 외래 진료소
- 기타
제9장 세계의 백반증 치료 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제10장 경쟁 상황
- 개요
- 경쟁 벤치마킹
- 주요 성장 전략
- 개발수로 탑 기업
- 주요 개발 분석
- 주요 전개·성장 전략
- 주요 기업 판매량 분석
제11장 기업 개요
- INCYTE
- BAUSCH HEALTH COMPANIES INC.
- KONINKLIJKE PHILIPS N.V.
- DR. REDDY'S LABORATORIES LTD.
- STRATA SKIN SCIENCES
- CLINUVEL PHARMACEUTICALS LTD
- ISSAR PHARMACEUTICALS PVT. LTD.
- KERNEL MEDICAL EQUIPMENT CO., LTD.
- LIGHTSOURCES
- ROIVANT SCIENCES LTD.
제12장 부록
ksm 24.10.11Global Vitiligo Treatment Market Research Report Information by Type (Segmental Vitiligo, Non-Segmental Vitiligo), By Treatment (Therapy, Surgery, Medication), By End-User (Hospitals, Ambulatory Clinics, Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)-Forecast till 2030
Market Overview
The Vitiligo Treatment Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.20% during the forecast period. The market is experiencing growth due to the increasing prevalence of vitligo, the increasing significance of aesthetic appeal and awareness, and the advancements in treatment options.
As a result of the increasing per capita income, the adoption of digital platforms, and the increasing awareness of various aesthetic treatments, there has been a substantial increase in beauty consciousness among consumers in recent years. Between 2015 and 2019, the International Society of Aesthetic Plastic Surgery (ISAPS) reported a 27.3% increase in the global total of non-surgical procedures. Furthermore, the American Society of Plastic Surgeons (ASPS) reported that the number of minimally invasive aesthetic procedures increased by approximately 200% from 2000 to 2017. Additionally, in 2018, approximately 15.9 million minimally invasive cosmetic procedures were conducted, representing a 2% increase from 2017.
Market Segment Insights
Segmental Vitiligo and Non-Segmental Vitiligo comprise the Vitiligo Treatment Market segmentation by Type.
A treatment that encompasses therapy, surgery, and medication is the basis for market segmentation.
The end-user segmentation of the market is based on Hospitals, Ambulatory Clinics, and Others.
Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Vitiligo Treatment Market held the greatest market share. As a result of the growing awareness of skin disorders and the development of a more sophisticated healthcare infrastructure. Innovative treatments, such as advanced phototherapy, biologics, and topical medications, have been introduced as a result of the region's strong emphasis on research and development.
The market share of the European Vitiligo Treatment Market is anticipated to be the second largest, as a result of the trend toward the integration of Vitiligo Treatment and the favorable health policies. Additionally, the France Vitiligo Treatment Market is anticipated to be the fastest-growing market in the European region, while the German Vitiligo Treatment Market was attributed to holding the largest market share.
From 2024 to 2032, the Asia-Pacific Vitiligo Treatment market is anticipated to experience the most rapid growth. This is the result of improved access to advanced therapies, which is facilitated by rising healthcare expenditures and the improvement of healthcare infrastructure. Additionally, the increasing prevalence of vitiligo and the increasing demand for cosmetic and dermatological remedies are substantial market drivers.
The Middle East, Africa, and Latin America comprise the Rest of the World. The primary factors that are influencing the expansion of Vitiligo Treatment in the Middle East and Africa. The Middle East and Africa region has encountered Increased global awareness and destigmatization of vitiligo are resulting in a higher demand for effective treatments and an increase in the number of diagnoses.
Major Players
Incyte (US), Bausch Health Companies Inc (Canada), Koninklijke Philips N.V. (Netherlands), Reddy's Laboratories Ltd (India), Strata Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), ISSAR Pharmaceuticals Pvt. Ltd (India), Kernel Medical Equipment CO., LTD (China), LightSources (US), and Roivant Sciences Ltd. (Switzerland) are among the key companies in the Vitiligo Treatment Market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
- 1.1 OVERVIEW
- 1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA MINING
- 3.3 SECONDARY RESEARCH
- 3.4 PRIMARY RESEARCH
- 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS
- 4.2.2 INCREASING PREVALENCE OF VITLIGO
- 4.3 RESTRAINTS
- 4.3.1 LACK OF TRAINED PROFESSIONALS
- 4.4 OPPORTUNITIES
- 4.4.1 RISING NUMBER OF CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON REGION
- 5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE
- 6.1 OVERVIEW
- 6.2 SEGMENTAL VITILIGO
- 6.3 NON-SEGMENTAL VITILIGO
7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE
- 7.1 OVERVIEW
- 7.2 THERAPY
- 7.2.1 DEPIGMENTATION
- 7.2.2 LIGHT
- 7.3 SURGERY
- 7.3.1 SKIN GRAFTING
- 7.3.2 BLISTER GRAFTING
- 7.3.3 MICRO-PIGMENTATION
- 7.4 MEDICATION
- 7.4.1 TOPICAL CORTICOSTEROIDS
- 7.4.2 IMMUNOSUPPRESSIVE
8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER
- 8.1 OVERVIEW
- 8.2 HOSPITALS
- 8.3 AMBULATORY CLINICS
- 8.4 OTHERS
9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION
- 9.1 OVERVIEW
- 9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
- 9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
- 9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 JAPAN
- 9.4.3 INDIA
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
- 9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 COMPETITIVE BENCHMARKING
- 10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET
- 10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET
- 10.5 KEY DEVELOPMENT ANALYSIS
- 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
- 10.6.2 MERGERS & ACQUISITIONS
- 10.7 MAJOR PLAYERS SALES ANALYSIS
- 10.7.1 SALES & OPERATING INCOME,
- 10.7.2 MAJOR PLAYERS R&D ANALYSIS,
11 COMPANY PROFILE
- 11.1 INCYTE
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
- 11.2 BAUSCH HEALTH COMPANIES INC.
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
- 11.3 KONINKLIJKE PHILIPS N.V.
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
- 11.4 DR. REDDY'S LABORATORIES LTD.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
- 11.5 STRATA SKIN SCIENCES
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
- 11.6 CLINUVEL PHARMACEUTICALS LTD
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
- 11.7 ISSAR PHARMACEUTICALS PVT. LTD.
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL ANALYSIS
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
- 11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.
- 11.8.1 COMPANY OVERVIEWS
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
- 11.9 LIGHTSOURCES
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL ANALYSIS
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
- 11.10 ROIVANT SCIENCES LTD.
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL ANALYSIS
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 PRODUCTS OFFERED
- 11.10.6 KEY STRATEGIES
12 APPENDIX
- 12.1 REFERENCES
- 12.2 RELATED REPORTS
